CUE VS SY Stock Comparison

Performance

CUE
10/100

CUE returned -33.33% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

SY
100/100

SY returned 60.01% in the last 12 months. Based on SPY's performance of -11.17%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

CUE
75/100

1 analysts offer 12-month price targets for CUE. Together, they have an average target of 7, the most optimistic target put CUE at 7 within 12-months and the most pessimistic has CUE at 7.

SY

"Analyst Price Targets" not found for SY

Sentiment

CUE
74/100

CUE had a bullish sentiment score of 74.32% across Twitter and StockTwits over the last 12 months. It had an average of 2.59 posts, 1.65 comments, and 3.88 likes per day.

SY
73/100

SY had a bullish sentiment score of 73.33% across Twitter and StockTwits over the last 12 months. It had an average of 1.40 posts, 0.00 comments, and 0.00 likes per day.

Technicals

CUE
64/100

CUE receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

SY
43/100

SY receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

CUE
10/100

CUE has missed earnings 6 times in the last 20 quarters.

SY
10/100

SY has missed earnings 9 times in the last 20 quarters.

Profit

CUE
10/100

Out of the last 20 quarters, CUE has had 0 profitable quarters and has increased their profits year over year on 0 of them.

SY
46/100

Out of the last 20 quarters, SY has had 12 profitable quarters and has increased their profits year over year on 4 of them.

Volatility

CUE
40/100

CUE has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

SY
55/100

SY has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Cue Biopharma, Inc. Summary

Nasdaq / CUE

Healthcare

Biotechnology

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

So-Young International Inc. American Depository Shares Summary

Nasdaq / SY

Healthcare

Medical - Healthcare Information Services

So-Young International Inc. operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments in the People's Republic of China and internationally. Its platform enables users to discover content and share their own experience on medical aesthetics procedures and leads users to reserve treatment services from medical aesthetic service providers for offline treatment. The company facilitates research on medical aesthetic treatment trends; ratings and reviews on treatment experiences; and blogs under the name Beauty Diaries. It also provides reservation services in the areas of dermatology, dentistry and orthodontics, ophthalmology, physical examinations, gynecology, human papilloma virus vaccines, and postnatal care; Software as a Service; and guiding and consulting services through training programs for medical service providers. In addition, the company offers internet information and technology advisory, management consulting, and Internet culture services, as well as sells medical equipment; equipment production, sales, and agency services; and micro finance services. As of December 31, 2021, it had approximately 8,400 medical aesthetic service providers and 5,000 other consumption healthcare service providers on its platform. The company was founded in 2013 and is headquartered in Beijing, China.

Power up your portfolio